Abstract
Several drugs have demonstrated clinical activity in metastatic renal cell carcinoma (mRCC). The identification of key metabolic pathways has led to the development of novel targeted therapies which have drastically changed the treatment paradigm of mRCC. Moreover, immune-checkpoint inhibitors have recently shown significant activity in advanced disease. Despite these advancements, the role of adjuvant therapy in localized, non-metastatic RCC remains unclear. The utility of many of these agents in the adjuvant setting is currently being actively explored. In this review, we will summarize the main clinical trials investigating adjuvant therapy in renal cell carcinoma, focusing primarily on immunotherapy and targeted agents.
| Original language | English |
|---|---|
| Pages (from-to) | 152-157 |
| Number of pages | 6 |
| Journal | Cancer Treatment Reviews |
| Volume | 60 |
| DOIs | |
| Publication status | Published - Nov 1 2017 |
Fingerprint
Keywords
- Adjuvant treatment
- Clear cell renal cell carcinoma
- Immunotherapy
- Renal cell carcinoma
- Tyrosine kinases inhibitors
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
Cite this
Adjuvant therapy in renal cell carcinoma. / Massari, Francesco; Di Nunno, Vincenzo; Ciccarese, Chiara; Graham, Jeffrey; Porta, Camillo; Comito, Francesca; Cubelli, Marta; Iacovelli, Roberto; Heng, Daniel Y.C.
In: Cancer Treatment Reviews, Vol. 60, 01.11.2017, p. 152-157.Research output: Contribution to journal › Review article
}
TY - JOUR
T1 - Adjuvant therapy in renal cell carcinoma
AU - Massari, Francesco
AU - Di Nunno, Vincenzo
AU - Ciccarese, Chiara
AU - Graham, Jeffrey
AU - Porta, Camillo
AU - Comito, Francesca
AU - Cubelli, Marta
AU - Iacovelli, Roberto
AU - Heng, Daniel Y.C.
PY - 2017/11/1
Y1 - 2017/11/1
N2 - Several drugs have demonstrated clinical activity in metastatic renal cell carcinoma (mRCC). The identification of key metabolic pathways has led to the development of novel targeted therapies which have drastically changed the treatment paradigm of mRCC. Moreover, immune-checkpoint inhibitors have recently shown significant activity in advanced disease. Despite these advancements, the role of adjuvant therapy in localized, non-metastatic RCC remains unclear. The utility of many of these agents in the adjuvant setting is currently being actively explored. In this review, we will summarize the main clinical trials investigating adjuvant therapy in renal cell carcinoma, focusing primarily on immunotherapy and targeted agents.
AB - Several drugs have demonstrated clinical activity in metastatic renal cell carcinoma (mRCC). The identification of key metabolic pathways has led to the development of novel targeted therapies which have drastically changed the treatment paradigm of mRCC. Moreover, immune-checkpoint inhibitors have recently shown significant activity in advanced disease. Despite these advancements, the role of adjuvant therapy in localized, non-metastatic RCC remains unclear. The utility of many of these agents in the adjuvant setting is currently being actively explored. In this review, we will summarize the main clinical trials investigating adjuvant therapy in renal cell carcinoma, focusing primarily on immunotherapy and targeted agents.
KW - Adjuvant treatment
KW - Clear cell renal cell carcinoma
KW - Immunotherapy
KW - Renal cell carcinoma
KW - Tyrosine kinases inhibitors
UR - http://www.scopus.com/inward/record.url?scp=85030761088&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85030761088&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2017.09.004
DO - 10.1016/j.ctrv.2017.09.004
M3 - Review article
C2 - 28992528
AN - SCOPUS:85030761088
VL - 60
SP - 152
EP - 157
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
ER -